Primary small cell carcinoma (SCC) of the breast, an exceedingly rare and aggressive tumor, is often characterized by rapid progression and poor prognosis. We report a case of primary SCC of the breast that was diagnosed through pathologic and immuno
Small cell carcinomas (SCC) commonly arise in the respiratory tract; however, it is not uncommon for these cells to arise in nonpulmonary sites, as extrapulmonary small cell carcinoma (EPSCC). Small cell carcinoma is a distinct clinical and pathologic entity that arises from cells of the amine precursor uptake and decarboxylation (APUD) system.
Small cell carcinomas (SCC) commonly arise in the respiratory tract; however, it is not uncommon for these cells to arise in nonpulmonary sites, as extrapulmonary small cell carcinoma (EPSCC). Small cell carcinoma is a distinct clinical and pathologic entity that arises from cells of the amine precursor uptake and decarboxylation (APUD) system.
A specific, acquired chromosomal abnormality (deletion 3p) has been found in at least one chromosome 3 in 100 percent of the metaphases in 12 of 12 cell lines cultured from human small-cell lung cancer tissue and in 2-day tumor culture specimens from three patients. Analysis of the shortest region of overlap shows the deletion to be 3p(14-23). This specific change was not seen in five of five lung cancer cell lines other than small-cell lung cancer or in two lymphoblastoid lines cultured from cells of small-cell lung cancer patients whose tumors had the 3p deletion. ...
Purpose and methods: To develop a clinically useful approach to circumvent P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) in MDR human small-cell lung cancer (SCLC), we examined the ability of a novel quinoline compound, MS-209, to reverse MDR by inhibition of P-gp function in combination with other MDR-reversing drugs using a cytotoxicity assay. Results: We established MDR human SCLC cells by culture in medium with gradually increasing concentrations of adriamycin (ADM). Compared with the parental human SCLC cells, SBC-3, the MDR variant SBC-3 cells obtained (SBC-3/ADM) were highly resistant to various chemotherapeutic agents due to P-gp expression. MS-209 reversed the resistance to ADM and vincristine (VCR) of SBC-3/ADM and H69/VP cells in a dose-dependent manner. Moreover, MS-209 in combination with cyclosporin A (CsA) or verapamil (VER) synergistically enhanced the antitumor effects of ADM and VCR on SBC-3/ADM cells. MS-209 restored ADM incorporation and this effect was enhanced by CsA
Small cell carcinoma of the urinary bladder (SCCB) is an extremely rare but aggressive tumour constituting less than 0.7% of all urinary bladder tumours.
TY - JOUR. T1 - F-18-FDG-PET/CT imaging of small cell carcinoma of the colon. AU - Jones, Katie. AU - Subramaniam, Rathan M.. AU - Durnick, David K.. AU - Peller, Patrick J.. PY - 2008/9/1. Y1 - 2008/9/1. N2 - Small cell carcinoma of the colon is a rare entity, comprising only 1.5% of all colon cancers. It is an aggressive neoplasm with rapid local progression and early metastasis. We present a case report of F-18 FDG PET/CT features of small cell carcinoma arising in the ascending colon of an 86-year-old woman who presented with anemia and melena. FDG PET/CT demonstrated a small, intense focus of FDG hypermetabolism in the cecum. Extrapulmonary small cell carcinoma, described in the salivary glands, pharynx, esophagus, stomach, small bowel, colon, rectum, gallbladder, uterus, kidney, and skin, has a poor prognosis when involving the gastrointestinal tract.. AB - Small cell carcinoma of the colon is a rare entity, comprising only 1.5% of all colon cancers. It is an aggressive neoplasm with rapid ...
This survey study compares use of prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer before and after the publication of a
RATIONALE: The general results of combining irinotecan and platin-based chemotherapies have been very encouraging. As the toxicity profile associated with carboplatin is preferable over cisplatin it is our expectation that patients and physicians would prefer to use this combination if it is equally or more efficacious. To date there has been no agreement regarding the optimal combination of these agents. Based on the trials described in the protocol and our experience with carboplatin/irinotecan in the treatment of non-small cell lung cancer the present trial will utilize a 21-day cycle of irinotecan 50 mg/m2 given on days 1 and 8 and carboplatin AUC 5 (based on the Calvert formula) on day 1.. PURPOSE: This phase II trial is studying how well giving irinotecan together with carboplatin works as first-line therapy in treating patients with extensive-stage small cell lung cancer. ...
RATIONALE: Drugs used in chemotherapy, such as cisplatin, etoposide, and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.. PURPOSE: This phase II trial is studying how well giving cisplatin, etoposide, and cyclophosphamide together works in treating patients with extensive-stage small cell lung cancer. ...
BioAssay record AID 81529 submitted by ChEMBL: Cytotoxicity against NCI tumor panel, HOP-92 non small-cell lung cancer cell line.
This study evaluated the prognosis of patients with extensive-stage small-cell lung cancer (ES-SCLC) that may be associated with timing of thoracic radiotherapy (TRT). ES-SCLC patients (n = 232) without progression were retrospectively analyzed after first-line induction chemotherapy. Patients in the TRT group were stratified as early-TRT (ERT; ≤3 cycles of induction chemotherapy received prior to TRT, n = 65) or late-TRT (LRT; |3 cycles, n = 122). To avoid selection bias, we conducted Propensity Score Matching (PSM) for patients. Overall survival (OS), progression-free survival (PFS), and locoregional recurrence-free survival (LRRFS) were assessed and compared. Overall, the median survival time, PFS, and LRRFS were 13.2, 8.7, and 14.6 months, respectively. After matching by PSM, there were 45 patients total in the TRT/non-TRT groups, and 56 patients total in the ERT/LRT groups. OS, PFS, and LRRFS were significantly longer in the TRT group than the non-TRT group (P | 0.001, all). However, between the
This study evaluated the prognosis of patients with extensive-stage small-cell lung cancer (ES-SCLC) that may be associated with timing of thoracic radiotherapy (TRT). ES-SCLC patients (n = 232) without progression were retrospectively analyzed after first-line induction chemotherapy. Patients in the TRT group were stratified as early-TRT (ERT; ≤3 cycles of induction chemotherapy received prior to TRT, n = 65) or late-TRT (LRT; |3 cycles, n = 122). To avoid selection bias, we conducted Propensity Score Matching (PSM) for patients. Overall survival (OS), progression-free survival (PFS), and locoregional recurrence-free survival (LRRFS) were assessed and compared. Overall, the median survival time, PFS, and LRRFS were 13.2, 8.7, and 14.6 months, respectively. After matching by PSM, there were 45 patients total in the TRT/non-TRT groups, and 56 patients total in the ERT/LRT groups. OS, PFS, and LRRFS were significantly longer in the TRT group than the non-TRT group (P | 0.001, all). However, between the
TY - JOUR. T1 - Limited-stage small-cell lung cancer. T2 - Patterns of intrathoracic recurrence and the implications for thoracic radiotherapy. AU - Liengswangwong, V.. AU - Bonner, J. A.. AU - Shaw, E. G.. AU - Foote, R. L.. AU - Frytak, S.. AU - Eagan, R. T.. AU - Jett, J. R.. AU - Richardson, R. L.. AU - Creagan, E. T.. AU - Su, J. Q.. PY - 1994/3. Y1 - 1994/3. N2 - Purpose: This analysis was performed to determine the most appropriate volume that should be encompassed by thoracic radiation treatments (TRTs) for patients with limited-stage small-cell lung cancer (LSSCLC) who have responded to initial chemotherapy. Patients and Methods: A retrospective review of all patients (N = 67) with LSSCLC who were not entered onto a research protocol and were treated at our institution between the years of 1982 and 1990 was performed. Fifty-nine of 67 patients had adequate information regarding the size of the tumor before the start of chemotherapy (computed tomographic [CT] scan of chest or chest ...
For the second time this month, the FDA has given an approval to Genentechs PD-L1 inhibitor, Tecentriq.. On March 18, 2019, the FDA awarded the immunotherapy agent, Tecentriq (atezolizumab; Genentech), in combination with chemotherapy (carboplatin and etoposide), approval for the first-line treatment of adults with extensive-stage small-cell lung cancer (ES-SCLC).. As evidence of the rapidity with which the immunotherapy field is gaining ground in cancer treatment, this new approval comes only 10 days after the drug received an accelerated approval (in combination with nab-paclitaxel) for the treatment of triple-negative breast cancer. Not only is this the second approval for atezolizumab in close succession to the first, but it is the first novel treatment in 2 decades for ES-SCLC, an aggressive and deadly malignancy.. This latest approval was based on data from the phase 3 IMpower133 trial, which was the first study to show that initial treatment with the immunotherapy-based combination ...
TY - CHAP. T1 - Bombesin stimulates growth of human small cell lung carcinoma in vivo. AU - Alexander, R. W.. AU - Upp, J. R.. AU - Poston, G. J.. AU - Gupta, V.. AU - Townsend, Courtney. AU - Thompson, J. C.. PY - 1987. Y1 - 1987. UR - http://www.scopus.com/inward/record.url?scp=0023610349&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0023610349&partnerID=8YFLogxK. M3 - Chapter. AN - SCOPUS:0023610349. VL - 38. SP - 450. EP - 452. BT - Surgical Forum. ER - ...
Radiotherapy improves the survival of patients with extensive-disease small-cell lung cancer: a propensity score matched analysis of Surveillance, Epidemiology, and End Results database Rui Zhang,* Ping Li,* Qin Li, Yunfeng Qiao, Tangpeng Xu, Peng Ruan, Qibin Song, Zhenming Fu Cancer Center, Renmin Hospital of Wuhan University, Wuhan 430060, China *These authors contributed equally to this work Background: The survival advantage of radiotherapy for patients with extensive-disease small-cell lung cancer (ED-SCLC) has not been adequately evaluated.Methods: We analyzed stage IV SCLC patients enrolled from the Surveillance, Epidemiology, and End Results (SEER) registry through January 2010 and December 2012. Propensity score analysis with 1:1 matching was performed to ensure well-balanced characteristics of all comparison groups. Kaplan–Meier and Cox proportional hazardous model were used to evaluate the overall survival (OS), cancer-specific survival (CSS), and corresponding 95% CI.Results: Overall,
Cell lines derived from human small cell carcinoma of the lung express high levels of a surface polypeptide termed the cluster-w4 antigen, which was previously identified as a potential target for toxin-based immunotherapy of lung cancer. We have cloned a complementary DNA encoding the cluster-w4 antigen from COS-1 fibroblasts transfected with a SW2 small cell carcinoma library, by panning with a mixture of the cluster-w4-specific monoclonal antibodies SWA11, SWA21, and SWA22. The sequence of the cluster-w4 complementary DNA encodes an unusually short (80-amino acid) protein identical to that recently reported for the leukocyte activation molecule CD24 except for a single valine-alanine substitution due to a single-base polymorphism within the region of the gene coding for the extracellular domain. Biochemical analyses of the cloned cluster-w4 antigen confirmed both the presence of the phosphatidylinositol tail and the extensive glycosylation reported for the CD24 molecule. Furthermore, the cloned
BACKGROUND: Small cell anaplastic carcinoma most commonly presents as a lesion in the central portion of the lung but occasionally is found in peripheral locations. Only seven cases originating in the breast have been described. To our knowledge, the preoperative diagnosis of this entity by fine needle aspiration has not been previously reported in the cytologic literature. CASE: A 67-year-old female presented with a 4 x 3-cm, rapidly growing mass in the left breast. On fine needle aspiration (FNA) the tumor was soft to the needle and yielded a highly cellular aspirate. CONCLUSION: In this case the morphologic interpretation of FNA, combined with the immunocytochemical demonstration of neuron-specific enolase in tumor cells, was extremely helpful in establishing the nature of the breast tumor.
TY - JOUR. T1 - Induction of hydrogen peroxide production and bax expression by caspase- 3(-like) proteases in tyrosine kinase inhibitor-induced apoptosis in human small cell lung carcinoma cells. AU - Simizu, Siro. AU - Umezawa, Kazuo. AU - Takada, Minoru. AU - Arber, Nadir. AU - Imoto, Masaya. PY - 1998/1/10. Y1 - 1998/1/10. N2 - In our previous studies (S. Simizu, et al., 1996, Cancer Res. 56, 4978- 4982), we reported that apoptosis of human small cell lung carcinoma (SCLC) cells induced by protein tyrosine kinase inhibitors, such as erbstatin and herbimycin A, was mediated by H2O2 via a newly synthesized protein(s). In the present study, we demonstrated that induction of apoptosis by erbstatin resulted in activation of caspase-3(like) proteases, which are interleukin- 1β-converting enzyme family proteases (caspases) and that inhibition of these protease activities reduced the extent of cell death and H2O2 generation. We also demonstrated that expression of apoptotic protein Bax was induced ...
SCLC accounts for about 15% of all lung cancers, and it is strongly associated with tobacco use. SCLC is an aggressive cancer type, with a 5-year overall survival rate of about 6% to 7%. Although a number of combinations have been studied, until the recent advent of immune checkpoint inhibitors, standard first-line therapy for extensive-stage SCLC had remained etoposide/platinum for the preceding 30 years, Dr. Rudin noted. Although patients respond to etoposide/platinum, the median overall survival on this regimen is less than 1 year.. Pembrolizumab is currently U.S. Food and Drug Administration-approved for use as third-line or later therapy for metastatic SCLC. This study sought to explore its use in the first-line setting for SCLC.. Study Details. KEYNOTE-604 was conducted at 133 sites in 18 countries and randomly assigned 453 patients with previously untreated disease in a 1:1 ratio to pembrolizumab/etoposide/platinum or placebo/etoposide/platinum. Pembrolizumab was given as 200 mg once ...
Lung cancer is the most common cancer and also the leading cause of cancer-related death worldwide among both men and women. Small cell lung cancer (SCLC) accounts for 15% of all cases. It is the most aggressive one in its clinical behavior with a 5-year overall survival as low as 5%. Focal Adhesion Kinase (FAK) is a non-receptor tyrosine kinase which regulates integrin and growth factor signaling pathways involved in cell proliferation, survival, migration, and invasion. FAK is overexpressed and/or activated in many cancers including SCLC. We hypothesized that FAK may represent a good target for therapeutic interventions in SCLC and tested the changes of cell phenotype induced by a FAK inhibitor (PF-228). ...
Currently, small-cell lung cancer accounts for about 15 percent of lung cancer diagnoses in the United States. Patients with the disease will initially respond to chemotherapy, but almost all will have disease recurrence within a couple of months, according to Lauren A. Byers, M.D., assistant professor of thoracic/head and neck medical oncology at The University of Texas MD Anderson Cancer Center in Houston.. "Unlike non-small cell lung cancer [NSCLC], where there have been new targeted drugs developed in the last ten years, the only currently approved treatments for small-cell lung cancer are cytotoxic chemotherapies," Byers said. "Because most targeted therapies directly act on proteins, identifying if certain proteins are overexpressed in small-cell lung cancer could have therapeutic applications.". In order to identify molecular differences between NSCLC and the more aggressive small-cell lung cancer, Byers and colleagues used tools called reverse phase protein arrays. These allow the ...
Jonathan Goldman, MD explains IMFINZI is the first immunotherapy to show both significant survival benefit and improved, durable responses in extensive-stage small cell lung cancer._______In the Phase III CASPIAN trial IMFINZI at a fixed, convenient dose improved survival with either a cisplatin or carboplatin chemotherapy backboneAstraZeneca today presented detailed results from the Phase III CASPIAN trial, showing IMFINZI® (durvalumab) significantly improved overall survival (OS) in patients with previously-untreated extensive-stage small cell lung cancer (SCLC). IMFINZI in combination with four cycles of standard-of-care (SoC) chemotherapy (etoposide with either cisplatin or carboplatin) demonstrated a statistically-significant and clinically-meaningful improvement in OS vs. SoC chemotherapy consisting of up to six cycles of chemotherapy and optional prophylactic cranial irradiation (PCI). The risk of death was reduced by 27% (equal to a hazard ratio of 0.73), with median OS of 13.0 months for
Chemicals. ABT-737 ((R)-4-(3-dimethylamino-1-phenylsulfanylmethyl-propylamino)-N-{4-[4-(4′-chloro-biphenyl-2-ylmethyl)-piperazin-1-yl]-benzoyl}-3-nitro-benzenesulfonamide) was synthesized at Abbott Laboratories (Abbott Park, IL). Carboplatin and etoposide were purchased from Sigma (St. Louis, MO).. Cell culture. The SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114 were purchased from the American Type Culture Collection (Manassas, VA). Cells were cultured in RPMI 1640 (Invitrogen Corp., Grand Island, NY) supplemented with 10% fetal bovine serum (Invitrogen), 1% sodium pyruvate, 25 mmol/L HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin (Sigma). All cell lines were maintained in a humidified chamber at 37°C containing 5% CO2.. The ABT-737-resistant H146 cells were derived from H146 cells by initially adding 40 nmol/L ABT-737 to their culture medium and thereafter doubling the concentration over a period of several ...
TY - JOUR. T1 - Delayed leuko-encephalopathy in survivors with small cell lung cancer. AU - So, N. K.. AU - ONeill, B. P.. AU - Frytak, S.. AU - Eagan, R. T.. AU - Earnest, F.. AU - Lee, R. E.. PY - 1987/7. Y1 - 1987/7. N2 - Six patients with small cell lung cancer developed a. slowly progressive neurologic syndrome characterized by apathy, abulia, memory loss, gait ataxia, and corticospinal tract signs 26 to 50 months (mean, 35.2 months) after prophylactic cranial irradiation and systemic chemotherapy. In each case this was accompanied by CT and/or MRI evidence of changes in the peri-ventricular white matter. These patients are long-term survivors (41 to 69 months) and do not have CNS metastases.. AB - Six patients with small cell lung cancer developed a. slowly progressive neurologic syndrome characterized by apathy, abulia, memory loss, gait ataxia, and corticospinal tract signs 26 to 50 months (mean, 35.2 months) after prophylactic cranial irradiation and systemic chemotherapy. In each case ...
Lung cancer is a common malignant tumor including Small Cell Lung Cancer (SCLC) with 10 - 15 % and Non-Small Cell Lung Cancer (NSCLC) with 70 - 80%. Currently, there are several approaches to be used to treat lung cancer including surgery, chemotherapy, radiation therapy and molecular therapy/immunotherapy, Metastatic SCLC, metastatic mixed type of lung cancer and unclassified lung cancer are still difficult to be cured because this kind of lung cancer is easy to be widely disseminated. For example, if a patient has several metastatic SCLC, the patient will reveal poor outcome. In order to resolve the poor prognosis with recurrent and metastatic SCLC, here we reported a pathway-based approaches for analysis of Genome-Wide Association Studies (GWAS) to screen drugs, hence we used the drugs to treat a patient suffering from SCLC with multiple metastases. In the beginning, we harvested a pair of SCLC cells and normal cells from FFPE samples under laser capture microscopy to achieve the tumor cell DNA for
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Imatinib mesylate may stop t
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may
Description: Neuroendocrine xenograft model of human prostatic small cell carcinoma cancer. Provides a source to study the involvement of neuroendocrine cells in the progression of prostatic adenocarcinoma and can serve as a novel model for the testing of new therapeutic strategies for prostatic small cell carcinoma.. WISH-PC2: Taken from a patient diagnosed with T3N1M1 prostatic adenocarcinoma with a Gleason score of 8 (3 + 5). Obtained during a palliative transuretheral resection of the prostate. Independent of Androgen and does not secretes prostate-specific antigen.. WISH-PC14: Taken from a channel transurethral resection of the prostate of a late recurrent primary tumor, Gleason score 9 (4 + 5), after definitive radiation therapy. Androgen dependent and secretes prostate-specific antigen. WISH-PC23: Taken from prostatic adenocarcinoma harvested during palliative trans urethral resection of the prostate performed in a patient with local progression of adenocarcinoma of the prostate, Gleason ...
Small cell lung cancer information with its causes along with various signs and symptoms. The fluid in the lungs may be an indication of this cancer but this may not be a sure sign of the disease. Detailed description of small cell lung cancer different treatment methods also given.
Each year, 13 percent of all newly diagnosed lung cancer patients are diagnosed with small-cell lung cancer (SCLC). Approximately 39 percent of patients with SCLC are diagnosed with limited-stage disease, meaning the cancer ...
Management of limited small cell lung cancer(SCLC). small cell lung cancer is very responsive to chemotherapy and radiotherapy. Most of the times it is disseminated. Surgery should only be done when chemotherapy has failed. Platinum compounds and etoposide combined with thoracic radiation is used. Prognosis and survival in small cell lung cancer; mosts of the times the patients present with a disseminated disease. If not treated, patients can survive for up to four months. when treated early, patients can live up to two years without the disease. About 5-10% of patients treated live up to five years.. Management of advanced small cell lung cancer(SCLC). The first line drugs in treatment of advanced small cell lung cancer is a combination of carboplastin or cisplatin combined with etoposide. Patients with small cell lung cancer have poor survival rates of ten months to two years in about 10% of the patients. ...
Small cell lung cancer accounts for approximately 15% of all lung cancers and has high metastatic potential and poor clinical outcomes. While untreated small cell lung cancers are usually highly sensitive to cytotoxic chemotherapy-with response rates of between 50% and 70%-patients often relapse, necessitating novel treatments strategies.. A phase I/II study of a combination of the poly ADP ribose polymerase (PARP) inhibitor olaparib and the chemotherapy agent temozolomide in patients with relapsed small cell lung cancer has found that the therapy had substantial clinical activity in these patients. In addition, a clinical study in animal models to identify molecular signatures that may be predictive of response to the therapy has found that a specific molecular signature of four inflammatory response genes could distinguish sensitive from resistant models in both the discovery and validation cohorts, and may provide a molecular signature of those tumors most likely to respond to ...
Get information, facts, and pictures about Small cell lung cancer at Encyclopedia.com. Make research projects and school reports about Small cell lung cancer easy with credible articles from our FREE, online encyclopedia and dictionary.
The identification of genes undergoing genetic or epigenetic alterations and contributing to the development of cancer is critical to our understanding of the molecular mechanisms of carcinogenesis. A new approach in identifying alterations of genes that might be relevant to the process of tumor development was used in this study by examining the gene expression profile in human lung cancer cells
Background: Much research has confirmed the favorable effect of irinotecan/cisplatin (IP) and etoposide/cisplatin (EP) on extensive-stage small cell lung c
The immunotherapy agent Keytruda (pembrolizumab) had an overall response rate (ORR) of 33 percent in a recent trial including patients with extensive-stage small cell lung cancer (SCLC). Findings of the phase 1b KEYNOTE-028 trial were published in the |em|Journal of Clinical Oncology.|/em|
Purpose: Neurocognitive impairment (NI) in patients with small cell lung cancer (SCLC) after whole brain radiation treatment (WBRT) is a significant cause of morbidity. Hippocampal avoidance (HA) during WBRT may mitigate or prevent NI in such patients. However, this has not been tested in SCLC patients. The estimated risk of metastases in the HA region (HM) in patients with SCLC at diagnosis or after WBRT is unknown. Our study aimed to determine the risk of HM in patients with SCLC and to assess correlated clinical factors. Methods and Materials: Patients with SCLC who experienced brain metastases (BM) at presentation (de novo) or after WBRT treated at the Saskatoon Cancer Centre between 2005 and 2012 were studied. Relevant neuroimaging was independently reviewed by a neuroradiologist. HM was defined as metastases within 5 mm of the hippocampus. Logistic regression analysis was performed to assess correlation between various clinical variables and HM. Results: Seventy eligible patients were ...
The combination of chemo- and radiotherapy has resulted in prolonged survival and potential cures in patients with some neoplastic diseases. Small cell lung cancer (SCLC) is one of those neoplasms in...
Introduction Just some brief information (numbers) on small cell lung cancer (SCLC) before I jump into treatments for advanced SCLC. 20% of all lung cancers 95% are cigarette smokers (remaining I strongly believe is caused by second hand smoke (SHS) or environmental tobacco smoke (ETC) also) 90% of the tumor is located centrally 70-80% are…
TY - JOUR. T1 - VP16-213 in combined modality treatment of small cell carcinoma of the lung. AU - Newman, Steven B.. AU - Bitran, Jacob D.. AU - Golomb, Harvey M.. AU - Hoffman, Philip C.. AU - DeMeester, Tom R.. AU - Raghavan, Vathsala. PY - 1982/1/1. Y1 - 1982/1/1. N2 - Thirty-four previously untreated patients with histologically proven small cell carcinoma of the lung were treated with a combined modality therapy program that incorporated VP16-213, an epipodophyllotoxin derivative, into the chemotherapy regimen. Initial therapy for two cycles was with V-CAM, VP16-213, cyclophosphamide, doxorubicin and methotrexate. Following two cycles of V-CAM each patient received radiation therapy consisting of 4000 rads to the primary site, both hila and the mediastinum, as well as 2000 rads as prophylaxis to the whole brain. After a one-week rest period the patients received monthly cycles of V-CAM until death. Of 10 patients with stage IIIM0 disease, 7 had a complete response (CR), 1 a partial response ...
... is also called oat cell cancer. About 10%-15% of lung cancers are small cell lung cancers. This type of lung cancer tends to spread quickly.
Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
TY - JOUR. T1 - Neutrophil-lymphocyte ratio is prognostic in early stage resected small-cell lung cancer. AU - Lohinai, Zoltan. AU - Bonanno, Laura. AU - Aksarin, Aleksei. AU - Pavan, Alberto. AU - Megyesfalvi, Zsolt. AU - Santa, Balazs. AU - Hollosi, Virag. AU - Hegedus, Balazs. AU - Moldvay, Judit. AU - Conte, PierFranco. AU - Ter-Ovanesov, Mikhail. AU - Bilan, Evgeniy. AU - Dome, Balazs. AU - Weiss, Glen J. PY - 2019/7/29. Y1 - 2019/7/29. N2 - Background: For selected early stage small cell lung cancer (SCLC), curative intent surgery is often performed. Previous studies, predominantly from East Asia, reported that high neutrophil to lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR) correlate with poor prognosis in several types of tumors including SCLC. Our aim was to investigate the prognostic value of NLR and PLR in Caucasian patients with resected SCLC, as potential tool to select patients for multimodal treatment including surgery.Methods: Consecutive patients evaluated at three ...
Researchers at Cancer Treatment Centers of America® (CTCA) at Western Regional Medical Center (Western), in collaboration with international colleagues, found that statins could be an effective therapeutic against metastatic small cell lung cancer. The study of 876 late-stage SCLC patients, published today in the scientific journal PLOS ONE, showed that statins, a class of drugs primarily used to lower cholesterol in patients at risk for heart disease, appeared to provide an increase in overall survival.
Small cell lung cancer treatment options include surgery, chemotherapy and radiation therapy, laser therapy, targeted therapy, and supportive care. Learn more about treatments for newly diagnosed and recurrent small cell lung cancer in this expert-reviewed summary.
Gastrin releasing peptide(GRP) is a 27 amino acid peptide isolated from the porcine gut. The last ten amino acids at the C-terminus of gastrin releasing peptide correspond with one amino acid alteration (3) to the last ten amino acids of bombesin, viz: H-Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2 .It has been reported (J. H. Walsh and J. R. Reeve, Peptides 6, (3), 63-68, (1985) that bombesin and bombesin-like peptides such as gastrin releasing peptide (GRP) are secreted by human small-cell lung cancer (SCLC) cells. It has been postulated (P. J. Woll and E. Rozengurt, PNAS 85, 1859-1863, (1988)) that gastrin releasing factor antagonists would bind competitively to bombesin receptors in animals and would therefore be of use in the treatment of SCLC and/or in the control of clinical symptoms associated with this disease and due to hypersecretion of this peptide hormone. Analogues of bombesin/ GRP have been shown to inhibit the binding of gastrin releasing peptide to a SCLC cell line and to inhibit ...
Small Cell Cancer (SCLC) is much more rare than Non-Small Cell, only about 15% of cases are Small Cell. Within SCLC, there are three different types: small cell carcinoma (oat cell cancer), mixed small cell/large cell carcinoma and combined small cell carcinoma. Most SCLC cases are oat cell. SCLC is the most aggressive form of lung cancer compared to the other type. It is mainly caused by smoking and starts in the bronchi (breathing tubes) in the center of the chest. This type of lung cancer grows quickly and produces large tumors. Because SCLC grows so quickly, it also metastasizes rapidly to other parts of the body including the brain, liver and bone. Metastasis is when a part of a cancerous tumor breaks off from the original tumor and spreads to another part of the body, spreading the cancer. When you have SCLC, there are many symptoms that come from it, including bloody sputum (spitting up blood), chest pain, coughing, loss of appetite, shortness of breath, weight loss, wheezing, facial ...
Small Cell Cancer (SCLC) is much more rare than Non-Small Cell, only about 15% of cases are Small Cell. Within SCLC, there are three different types: small cell carcinoma (oat cell cancer), mixed small cell/large cell carcinoma and combined small cell carcinoma. Most SCLC cases are oat cell. SCLC is the most aggressive form of lung cancer compared to the other type. It is mainly caused by smoking and starts in the bronchi (breathing tubes) in the center of the chest. This type of lung cancer grows quickly and produces large tumors. Because SCLC grows so quickly, it also metastasizes rapidly to other parts of the body including the brain, liver and bone. Metastasis is when a part of a cancerous tumor breaks off from the original tumor and spreads to another part of the body, spreading the cancer. When you have SCLC, there are many symptoms that come from it, including bloody sputum (spitting up blood), chest pain, coughing, loss of appetite, shortness of breath, weight loss, wheezing, facial ...